预约演示

更新于：2025-04-17

Chlorthalidone

氯噻酮

更新于：2025-04-17

概要

基本信息

简介氯噻酮是一种小分子药物，通过抑制负责肾脏中钠和氯化物重吸收的NCC蛋白起作用。这种药物是治疗尿崩症、高血压、肾结石和水肿的有用工具。赛诺菲是一家制药公司，于1959年率先开发并获得氯噻酮使用批准。作为一种利尿药物，氯噻酮通常用于通过增加尿液量和减少体内液体量来控制高血压。它在治疗一系列疾病方面的有效性，加上其悠久的历史，使其成为医疗领域的一种有价值的药物。

药物类型

小分子化药

别名

1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline、1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline、2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide

+ [17]

靶点

NCC

作用方式

抑制剂

作用机制

NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂)

治疗领域

神经系统疾病心血管疾病内分泌与代谢疾病+ [2]

在研适应症

尿崩症水肿高血压+ [1]

非在研适应症-

原研机构

Sanofi

在研机构

Casper Pharma LLC

成都第一制药有限公司PRM Pharma, LLC

非在研机构

Sanofi-Aventis U.S. LLC

最高研发阶段批准上市

首次获批日期

美国 (1960-04-07),

高血压

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C14H11ClN2O4S

InChIKeyJIVPVXMEBJLZRO-UHFFFAOYSA-N

CAS号77-36-1

关联

项与氯噻酮相关的临床试验

NCT02493322

/ Not yet recruiting临床3期

Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

开始日期2024-12-01

申办/合作机构

EMS SA (Brazil)

NCT02483936

/ Not yet recruiting临床3期

Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

开始日期2024-12-01

申办/合作机构

EMS SA (Brazil)

NCT06111885

/ Recruiting临床2期

Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention

The aim of this study is to test the efficacy of the two long-acting thiazide-like diuretics indapamide and chlorthalidone in reducing urine supersaturation for calcium oxalate and calcium phosphate compared to the short-acting thiazide diuretic hydrochlorothiazide for the prevention of calcium-containing kidney stones.

开始日期2024-10-01

申办/合作机构

Insel Gruppe AG

100 项与氯噻酮相关的临床结果

登录后查看更多信息

100 项与氯噻酮相关的转化医学

登录后查看更多信息

100 项与氯噻酮相关的专利（医药）

登录后查看更多信息

2,624

项与氯噻酮相关的文献（医药）

2025-04-01·JOURNAL OF CARDIAC FAILURE

Rationale and Design of the DECONGEST (Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment) Study

Article

作者: Verbeeck, Johan ; Verbrugge, Frederik H ; Verbrugge, Frederik H. ; Vanhentenrijk, Simon ; Wilson Tang, W.H. ; Vandoren, Vincent ; L'Hoyes, Wouter ; Choustoulakis, Eleftherios ; L'hoyes, Wouter ; Roosens, Bram ; Tang, W H Wilson ; Kalpakos, Theodoros ; Braeckeveldt, Laura ; Verwerft, Jan

AIMS:

To evaluate whether early-combination diuretic therapy guided by serial post-diuretic urine sodium concentration (UNa⁺) assessments in acute heart failure (AHF) facilitates safe and effective decongestion.

METHODS:

The Diuretic Treatment in Acute Heart Failure with Volume Overload Guided by Serial Spot Urine Sodium Assessment (DECONGEST) study is a pragmatic, 2-center, randomized, parallel-arm, open-label study aiming to enroll 104 patients with AHF and clinically evident fluid overload requiring treatment with intravenous loop diuretics. Patients are randomized to receive standard of care or a bundled approach comprising: (1) systematic post-diuretic UNa⁺ assessments until successful decongestion, defined as no remaining clinical signs of fluid overload with a post-diuretic UNa⁺ ≤ 80 mmol/L; (2) thrice-daily intravenous loop diuretic bolus therapy, with dosing according to estimated glomerular filtration rate; (3) upfront use of intravenous acetazolamide (500 mg once daily [OD]); and (4) full nephron blockade with high-dose oral chlorthalidone (100 mg OD) and intravenous canreonate (200 mg OD) for diuretic resistance, defined as persisting signs of fluid overload with a post-diuretic UNa⁺ ≤ 80 mmol/L. The primary endpoint of the DECONGEST study is a hierarchical composite of (1) survival at 30 days; (2) days alive and out of hospital or care facility up to 30 days; and (3) greater relative decrease in natriuretic peptide levels from baseline to day 30.

CONCLUSION:

The DECONGEST study aims to determine whether an intensive diuretic regimen focused on early combination therapy, guided by serial post-diuretic UNa+ assessments, safely enhances decongestion, warranting further evaluation in a larger trial powered for clinical events.

2025-03-01·AMERICAN JOURNAL OF MEDICINE

Chlorthalidone as Secondary Treatment in HFpEF?

Review

作者: Gelfman, Daniel M. ; Gelfman, Daniel M

This review addresses important issues that face practitioners today concerning the treatment of heart failure with preserved ejection fraction (HFpEF). It points out how the accepted efficacy of HFpEF medication treatment has changed. Medications are now recommended for use in HFpEF that have diuretic properties and are significant because of a reduction in the frequency of the development of heart failure (not mortality). This heart failure incidence reduction appears predictable and is valuable, but it raises the question of the use of chlorthalidone in the treatment of HFpEF. Chlorthalidone has previously been demonstrated to reduce heart failure incidence in the treatment of hypertensive patients, which is a similar patient population. Chlorthalidone, possibly with a generic mineralocorticoid antagonist, could be an acceptable low-cost alternate therapy as secondary treatment for HFpEF. Of course, chlorthalidone does not have the other theoretic benefits of the sodium-glucose cotransporter 2 (SGLT2) inhibitors or finerenone. It would be helpful if this was discussed in the upcoming HFpEF guidelines, especially for use in patients who cannot afford or tolerate the new HFpEF medications.

2025-03-01·JOURNAL OF CHROMATOGRAPHY A

Predicting retention on immobilized artificial membrane chromatography: Lipophilicity-based versus lipophilicity-independent models

Article

作者: Tsopelas, Fotios ; Vallianatou, Theodosia ; Tsantili-Kakoulidou, Anna

Retention of molecules on immobilized artificial membrane (IAM) chromatography is a key physicochemical property for predictive models of permeability across biological barriers, with applications in drug design and ecotoxicology. Currently, IAM retention is solely experimentally determined, which limits its utility for screening virtual compound libraries or for predictions of yet not synthesized molecules. The present study focuses on developing predictive models of IAM retention factors (logk_w(IAM)) for a structurally diverse set of drug compounds, scrutinizing the role of lipophilicity, experimental and calculated, as well as the contribution of additional molecular parameters, selected from a pool of physicochemical, constitutional, topological and 3D descriptors. After obtaining a data overview by principal component analysis, both multiple linear regression (MLR) and partial least squares (PLS) analyses were used to construct lipophilicity-based models and lipophilicity-independent models. Bulk, polarity and fraction of anionic species were common descriptors in all models. It was demonstrated that calculated lipophilicity values introduced additional uncertainty, depending on the software used. On the other hand, lipophilicity-independent MLR and PLS models, which relied solely on computational descriptors, showed comparable performance with lipophilicity-based models, while offering the advantage to more useful for screening large libraries in early drug discovery. The reliability of lipophilicity-independent MLR and PLS models was assessed by external validation as well as by using a blind test set. Error distribution between lipophilicity-based and lipophilicity-independent models was also investigated and found to be comparable, while it was better than the differences between experimental and calculated lipophilicity values.

项与氯噻酮相关的新闻（医药）

2025-03-31

·医学新视点

高血压临床常见问题，7问7答！

01什么是高血压的热胀冷缩现象？答：人的血压可随着季节更替而变化，呈现“秋冬高，春夏低”的特点。一般冬季血压比夏季明显增高。结果表明，夏季收缩压/舒张压平均值比冬季下降了3～5 mmHg。中国人群的流行病学研究结果表明，室外温度>5°C时，温度每降低10°C，收缩压平均升高6.2 mmHg。02夏季服用降压药需要注意哪些问题？答：夏季由于人体出汗多，电解质和水分排出也增多，因此要减少利尿剂类降压药的使用，以防止出现脱水及低血钾。高血压患者夏天夜间睡眠质量差，常会出现夜间血压升高，因此，夏天更适合选用长效、缓释降压药物。03高血压急症的降压原则是什么？答：高血压急症是一组以急性血压升高，伴有靶器官损伤，或原有功能受损进行性加重为特征的一组临床综合征。若收缩压≥220 mmHg和（或）舒张压≥140 mmHg，无论有无症状，都应视为高血压急症。降压原则：① 初始阶段（1 h内）血压控制目标为平均动脉压（MAP）的降低幅度不超过治疗前水平的25%；② 在随后的2~6 h将血压降至较安全水平，一般为160/100 mmHg左右，但需根据不同疾病的降压目标和降压速度进行后续的血压管理；③ 当病情稳定后，24~48 h血压逐渐降至正常水平。04难治性高血压的定义是什么？目前临床处理策略是什么？答：难治性高血压是指在改善生活方式的基础上，应用了合理可耐受的足量≥3种降压药物（包括利尿剂）治疗>1个月血压仍大于140/90 mmHg，或服用≥4种降压药物血压才能有效控制的高血压。处理策略：第一步，除外其他原因+保证低盐饮食+最大化生活方式干预+最佳3药方案（3种不同类型、机制互补的抗高血压药物，包括ACEI/ARB、长效CCB和利尿剂，使用最大剂量或最大耐受剂量，利尿剂类型须和肾功能相适应）；第二步，替换最佳剂量的噻嗪样利尿剂（可考虑使用氯噻酮或吲达帕胺来替代氢氯噻嗪）；第三步，加用醛固酮受体拮抗剂（螺内酯或依普利酮）；第四步，控制心率和β受体阻滞剂；第五步，上述效果不佳时可考虑肾动脉去神经术（RDN）。05房颤患者如何测血压？① 尽管房颤时听诊法或示波法的血压测量值准确性劣于窦性心律，但所测得的收缩压还是能满足需要，所以即使发生房颤还是需要测量血压；② 应连续测量3次，间隔1分钟，使用3次测量的平均值当做血压值，但是就目前研究而言，使用该方法测得的收缩压数值的准确性要优于舒张压；③ 当心率<90或100次/min，及3次测量的脉率变异性（示波法血压计3次测得的脉率数据的最大差值）<10次/min时，示波法测得的收缩压读数具有较高的可靠性；④ 使用示波法动态血压监测可提供更多次的血压数据，在一定程度上可提高血压评估的准确性。06什么是血压测量时听诊的korotkoff5期法？利用放在肱动脉的听诊器可以听到当袖带压小于肱动脉血压血流冲过被压扁动脉时产生的湍流引起的振动声（科罗特科夫声，简称科氏声）来测定血压值。第1期：放气后首先听到的响亮拍击声，此时汞柱所指刻度为收缩压读数；第2期：之后听到的柔和吹风样杂音；第3期：由于压力进一步降低而动脉血流量增加后，拍击声重新出现；第4期：音调突然变得沉闷；第5期：声音消失。一般声音突然变弱或消失时，汞柱所指刻度为舒张压读数。07低血压病患者应如何选择药物？答：低血压患者轻者如无任何症状，无需药物治疗。主要治疗为积极参加体育锻炼，改善体质，增加营养，多喝水，多吃汤，每日食盐略多于常人。重者伴有明显症状，必须给予积极治疗，改善症状，提高生活质量，防止严重危害发生。近年来推出米多君、利他林、麻黄素、氟氢可的松等药物，但其疗效有待进一步考察。08什么是体位性低血压？应如何预防和处理体位性低血压？答：体位性低血压是指由卧位变为直立体位的3分钟内，收缩压下降>20 mmHg或舒张压下降≥10 mmHg，也有一些老年人直立时间超过3分钟才出现明显的血压下降。预防方法：避免长时间站立，尤其在服药后最初几个小时；改变姿势，特别是从卧、坐位起立时动作宜缓慢；服药时间可选择在平静休息时，服药后继续休息一段时间再下床活动；如在睡前服药，夜间起床排尿时应注意。发生体位性低血压时应平卧，可抬高下肢超过头部，以促进下肢血液回流。相关阅读强效降压30 mmHg，心血管风险减少35%！强化降压或更适合代谢综合征管理血压＜120 mmHg更好？新研究发现，强化降压与死亡、心梗、心衰等风险降低相关JAHA：强化降压达到<140 mmHg，高血压患者就无需太担心中风风险《柳叶刀》：强化降压＜120 mmHg，获益更大！阜外医院李静团队领衔研究或改写指南中国人群最佳血压值来了？强化降压至此范围，心血管死亡风险降低39%！欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。参考资料（可上下滑动查看）[1]郭艺芳.高血压患者血压季节性变化临床管理中国专家共识[J].中华高血压杂志,2022,30(09):813-817.[2]中国急诊医学教育学院.中国高血压急症诊治规范[J].中华急诊医学杂志,2020,29(09):1154-1161.[3]Robert M. Carey, David A. Calhoun, George L. Bakris, et al. Resistant Hypertension: Detection, Evaluation, and Management：A Scientific Statement From the American Heart Association. Hypertension, originally published13 Sep 2018.[4]赵连友,孙英贤,苏海,等.心房颤动患者无创性血压测量问题的中国专家共识[J].中华高血压杂志,2022,30(10):909-914.[5]人民卫生出版社，诊断学，第九版，2018[6]Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology. 1996 May;46(5):1470.免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。分享，点赞，在看，传递医学新知

临床结果

2025-02-17

·医学新视点

慢性肾脏病患者血压≤120 mmHg更合理？

2025年世界肾脏病大会（WCN 2025）于2025年2月6日至9日在印度新德里举行。大会期间，热点辩论环节尤为引人关注，其中Swapnil Hiremath教授就与Indranil Dasgupta教授就“改善全球肾脏病预后组织（KDIGO）慢性肾脏病患者血压控制目标的现实可达性”这一主题展开了辩论。Swapnil Hiremath教授认为KDIGO慢性肾脏病患者血压控制目标是可及的，小编整理了Swapnil Hiremath教授的论述内容，一起来看看吧~ 关于降压目标的设定全球疾病负担数据显示，高血压与众多不良健康结局密切相关，尤其是心脏病和中风。普遍观点认为极高血压值（例如180 mmHg或160 mmHg）才构成威胁，但事实上，风险自血压达到120 mmHg时便已开始悄然上升。正因如此，多数心血管事件的发生往往集中在血压介于120~160 mmHg区间的人群中。因此，单纯因设定140 mmHg或160 mmHg等较为容易达成的血压目标值而妥协，并非科学的应对策略。这并非仅凭一个研究得出的结论，一项涵盖了多项大型试验的综合荟萃分析研究显示，血压每降低约10 mmHg，主要不良心血管事件（MACE）的风险就能显著降低约20%。血压与中风及心力衰竭的发生紧密相关，其适度下降可使中风和心力衰竭风险降低约30%，并使死亡风险降低约10%。治疗高血压的首要目的并非延缓慢性肾脏病（CKD）的进展，因为其对肾衰竭的直接影响相对有限。实际上，控制高血压主要是为了降低心脏病和中风的风险。或许有人认为，这应该是心脏病学家的职责范畴，而非肾病学家的任务。然而，这种观点有失偏颇，因为大多数CKD患者的致死原因并非肾衰竭或透析，而是心脏病。对于肾小球滤过率（GFR）低于60 ml/min/1.73m2的患者而言，心血管疾病更是首要死因。因此，若期望CKD患者拥有更长的生存期，就必须妥善管理其心血管风险因素，而控制血压无疑是其中的关键一环。那么，为何将120 mmHg作为血压控制的目标值呢？如前所述，血压每降低10 mmHg，相关风险便会降低。这一结论主要基于SPRINT试验的结果。在SPRINT试验中，总体数据显示，不仅MACE的风险降低了25%，全因死亡率也下降了约27%。深入探究SPRINT试验中的CKD亚组数据，我们发现，尽管该亚组的入组人数未达到预期，但仍能清晰展现出全因死亡率的持续下降趋势。在CKD患者中，全因死亡率降低了28%，心血管风险降低了43%。尽管样本量有限，但数据显示在CKD群体中，风险降低的幅度依然十分明显。既然如此，为何有人持反对观点？这或许是对老年患者的年龄顾虑。然而，当我们观察针对老年群体的数据，会发现其效果甚至更为显著。考虑到老年患者中风风险本就偏高，通过合理降压，可以帮助他们延长寿命。因此，年龄不应成为治疗的阻碍。既往指南将血压控制目标设定为140/90 mmHg，但SPRINT试验的发布突然提出了一个更为严格的目标——降至120 mmHg。这一挑战性的新标准自然引起了广泛争议，我认为这些声音应当被理性对待。 SPRINT试验是一项设计严密、执行严谨的研究，其结果支持了120 mmHg作为更优的血压控制目标。此外，中国的ESPRIT试验（纳入患者数超过SPRINT，达11000名）也采用了相似策略，研究结果显示，强化降压组和标准降压组的主要终点事件发生分别为547例（9.7%）和623例（11.1%），证实了将血压控制在120 mmHg以下可降低MACE风险。另外，近期发表的BPROAD试验（针对12000例糖尿病患者）同样显示，与140 mmHg相比，将血压控制在120 mmHg能降低MACE风险达21%。因此，设定更低的血压目标值（120 mmHg）对保护CKD患者的心脏，并降低死亡风险是有益的。关于血压测量的问题在血压测量方面，我们的表现确实不尽如人意。一项针对159名医学生的调研揭示，仅有一人能够准确执行血压测量操作。测量血压前有诸多注意事项，如避免饮用咖啡或茶、不吸烟以及保持膀胱排空等。膀胱充盈状态可能使血压升高约30 mmHg，因此确保患者在测量前排空膀胱至关重要。此外，正确的体位、快速放气等技巧虽已被倡导多年，但实施效果并不理想。在此背景下，自动血压测量设备显得尤为重要。尽管这些设备也曾备受争议，但它们在实际应用中确实展现出了有效性。例如，已停产的BP TRUE设备通过取五次测量的平均值，测量血压从147 mmHg降低至136 mmHg。另一项的研究也证实了这一点，使用与SPRINT试验类似的设备，测量血压降低了12.7 mmHg。这些研究强调了正确测量血压的重要性，以及采用自动化设备在提升测量准确性和效率方面的潜力。您或许会提出疑问，是否可以直接将手动测量值扣除13 mmHg作为标准血压？答案是否定的，因为误差的范围可能介于-46~+20之间。一项发表在《内科学年鉴》杂志的研究探讨了医护人员在场与否对血压测量结果的影响，结果表明，即便有他人在场，血压测量结果亦无显著差异。研究团队在巴尔的摩一个历史悠久的市场中进行了测量，尽管环境喧嚣，但通过实施5分钟的静息时间及采用正确技术，发现嘈杂环境与安静环境下的测量结果并无差异。这意味着，在候诊室内测量血压同样可行，无需因环境而担忧测量准确性。若未能准确测量血压，则不应轻易启动高血压治疗方案。上述试验中采用的测量手段（无论是自动化设备还是手动操作）均符合规范。血压控制的关键在于精确测量，正确的测量能让看似不可能达成的降压目标变得可及。关于药物治疗一项关于不依从性和难治性高血压的系统性综述研究显示，高血压患者的不依从性发生率高达约35%，而若采用直接观察疗法（DOT）或尿液检测，不依从的比例可能攀升至近半数。这一议题与Dasgupta医生的关注点紧密相关，相信他会认同患者的不依从性是一个不可忽视的关键因素。因此，当患者在增加药物剂量后血压仍居高不下时，请务必考虑不依从性的可能性。合理的药物使用可以用ACDc来记忆：A[血管紧张素转换酶抑制剂（ACEI）/血管紧张素II受体拮抗剂（ARB）]、C（钙通道阻滞剂）、D（利尿剂）。有一种误解认为噻嗪类利尿剂在CKD患者中无效。CLICK研究显示，即使在CKD患者中，使用低剂量的氯噻酮（6.25 mg或12.5 mg，隔日一次）也可以将血压降低约11 mmHg。当然，应用的同时我们也要注意避免不良反应。肌酐仅仅是一个数值，其临床意义需结合具体情况分析。当为患者采取治疗措施后，尽管肌酐值有所上升，但患者的临床状况得到改善，这种情况是可以接受的。我理解这并不容易，因为患者也在密切关注这个数值。例如，在治疗心力衰竭患者时，使用利尿剂后，肌酐值的上升往往是预期之内且积极的信号。然而，如果是由于其他原因（如败血症或肾毒性药物导致的急性肾损伤）引起的自发性肌酐上升，则需要另作考虑。我并非建议忽视急性肾损伤（AKI），但如果是为了治疗目的而诱导产生的AKI，许多研究表明，相关生物标志物并不会显著上升，此时肌酐数值的波动不必过分担忧。 Don't STOP-ACEi研究讨论了是否应在晚期CKD患者中停用ACEi和ARB。结果显示，如果停用这些药物，肌酐值会下降，但这并不会延缓肾病的进展。继续使用ACE抑制剂和ARB的患者，MACE风险降低了9%（尽管没有统计学意义）。另一项发表在《内科学年鉴》的研究讨论了在晚期CKD患者中使用ACEi和ARB的效果。结果显示，继续使用这些药物可以降低肾衰竭的风险。我想强调的是，对于蛋白尿阳性CKD患者、糖尿病CKD患者或心力衰竭患者，不要随意停用ACEi和ARB。患者有明确的适应证，可以继续使用这些药物。最后，关于α受体阻滞剂，从医学角度来看，α受体阻滞剂并未给患者带来实质性的益处，除了可能降低某些数值和提供短暂的心理安慰。众多研究已证实了这一点，尽管它们可能使肌酐值看似正常，且不会导致低钾血症，但实质上并未改善患者的健康状况。因此，我们应选择更合适的药物组合。例如，对于糖尿病患者、心力衰竭患者或有蛋白尿适应证的患者，SGLT2抑制剂是不错的选择。在动态血压监测（ABPM）下，SGLT2抑制剂也能有效降低血压约4~9 mmHg。此外，胰高血糖素样肽-1（GLP-1）受体激动剂也在许多地方逐渐得到认可。对于肥胖患者或CKD患者，GLP-1受体激动剂能够减轻体重并降低血压，因此值得考虑使用。相关阅读《自然-医学》：降糖、减重、降压，还能治肾病！司美格鲁肽“一药多效”再获力证 2024年指南：肾病9大食养建议，这样吃喝…更合理显著改善肾功能，创新肾病疗法2期临床结果登上NEJM 欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。分享，点赞，在看，传递医学新知

临床终止临床研究

2024-05-16

·PRNewswire

New Analysis on Hypertension Treatment to be Presented as Late-Breaking Research at National Kidney Foundation Spring Clinical Meetings

LONG BEACH, Calif., May 16, 2024 /PRNewswire/ -- A new analysis of a study comparing two commonly used medications, chlorthalidone (CTD) and hydrochlorothiazide (HCTZ), is set to be presented as a late-breaking presentation at the annual 2024 National Kidney Foundation Spring Clinical Meetings. Continue Reading The study, titled "Treatment with Chlorthalidone vs Hydrochlorothiazide and Renal Outcomes: The Diuretic Comparison Project (DCP)," conducted by a team of distinguished researchers from various institutions and led by Areef Ishani, MD MS, Minneapolis VA Health Care System Primary Care and Specialty Care Integrated Care Community (ICC) Director and Professor of Medicine, University of Minnesota provides crucial insights into the impact of these medications on renal health in hypertensive patients. New study comparing two commonly used medications set to be shared as a late-breaking presentation at NKF's Conference. Post this Hypertension, or high blood pressure, is a significant risk factor for the development and progression of chronic kidney disease (CKD). Previous research had hinted at potential differences in kidney outcomes between chlorthalidone and hydrochlorothiazide. This new study followed more than 12,000 participants for an average of 3.9 years. The study found no significant disparity in renal outcomes between patients treated with chlorthalidone and those treated with hydrochlorothiazide. Specifically, there was no marked difference observed in the primary composite renal outcome, including doubling of serum creatinine, a significant drop in estimated glomerular filtration rate (eGFR), or kidney failure requiring treatment (KFRT), between the two treatment groups. Furthermore, the study revealed that the total slope of eGFR change and the incidence of chronic kidney disease (CKD) were comparable between patients receiving chlorthalidone and hydrochlorothiazide, suggesting similar efficacy in preserving kidney function. The findings offer reassurance that both chlorthalidone and hydrochlorothiazide may be equally effective choices for managing hypertension without compromising renal health. About NKF Spring Clinical Meetings For the past 32 years, nephrology healthcare professionals from across the country have come to NKF's Spring Clinical Meetings to learn about the newest developments related to all aspects of nephrology practice; network with colleagues; and present their research findings. The NKF Spring Clinical Meetings is designed for meaningful change in the multidisciplinary healthcare teams' skills, performance, and patient health outcomes. It is the only conference of its kind that focuses on translating science into practice for the entire healthcare team. About Kidney Disease In the United States, more than 37 million adults are estimated to have kidney disease, also known as chronic kidney disease (CKD)—and approximately 90 percent don't know they have it. About 1 in 3 adults in the U.S. are at risk for kidney disease. Risk factors for kidney disease include: diabetes, high blood pressure, heart disease, obesity, and family history. People of Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian American, or Native Hawaiian or Other Pacific Islander descent are at increased risk for developing the disease. Black or African American people are about four times as likely as White people to have kidney failure. Hispanics experience kidney failure at about double the rate of White people. About NKF Professional Memberships Healthcare professionals can join NKF to receive access to tools and resources for both patients and professionals, discounts on professional education, and access to a network of thousands of individuals who treat patients with kidney disease. About the National Kidney Foundation The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. NKF Website Instagram Facebook X SOURCE The National Kidney Foundation

临床研究

100 项与氯噻酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00272	氯噻酮	C03BA04	DB00310

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
尿崩症	中国	成都第一制药有限公司	1985-01-01
水肿	中国	成都第一制药有限公司	1985-01-01
肾石病	中国	成都第一制药有限公司	1985-01-01
高血压	美国	Sanofi-Aventis U.S. LLC	1960-04-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02841280 (CLICK, Pubmed)	临床2期	慢性肾病 24-hour urinary sodium \| aldosterone \| plasma renin ... 更多	160	Chlorthalidone	襯製膚餘製繭膚夢憲鹽(蓋願襯願顧獵齋簾鑰醖) = 鏇餘選憲壓廠壓艱衊壓鹽範顧製鬱衊築選鹽蓋 (獵鏇鏇窪鏇範網鑰願衊, 25.4 ~ 57.4) 更多	积极	2024-06-12
ESH2024	N/A	冠心病 \| 原发性高血压	-	Metoprolol + Telmisartan + Chlorthalidone	壓觸願鹽簾遞鬱網淵選(觸製鏇遞鹽積壓築繭鹽) = hypotension being most common 繭鑰願鬱夢憲網壓衊鏇 (糧遞構積簾淵構憲窪築 )	积极	2024-05-01
NCT02665117 (CTgov)	N/A	高血压	61	Potassium Magnesium Citrate (KMgCit)+chlorthalidone (KMgCit + Chlorthalidone)	憲簾淵構鏇築鏇構糧簾(製選齋簾憲遞願遞觸襯) = 鹹鏇餘淵觸築窪範製簾衊窪淵製憲淵網糧獵構 (襯選鹽窪艱艱憲衊選製, 13.3) 更多	-	2023-10-25
				Potassium Chloride (KCl)+chlorthalidone (KCl + Chlorthalidone)	憲簾淵構鏇築鏇構糧簾(製選齋簾憲遞願遞觸襯) = 鏇鹹顧鏇繭醖餘觸願糧衊窪淵製憲淵網糧獵構 (襯選鹽窪艱艱憲衊選製, 9.9) 更多
SAT036 (ENDO2023)	N/A	2型糖尿病	1	Chlorthalidone 25mg daily	廠顧範鏇襯壓衊鏇簾淵(襯衊壓鏇積壓餘鏇鏇鏇) = acidosis resolved within 24 hours with IV fluid resuscitation and Insulin drip on DKA protocol 繭網醖襯築製衊淵窪觸 (艱網鹹獵積顧製鑰繭簾 ) 更多	不佳	2023-10-05
				Metformin 500mg twice daily
NCT02841280 (CLICK, CTgov)	临床2期	高血压 \| 慢性肾病	160	Chlorthalidone (Chlorthalidone)	製餘繭餘鹽衊醖鹹衊醖(淵膚壓製憲夢廠憲廠選) = 鏇積願遞積範艱構構夢願願選範顧簾壓鹹膚廠 (鹹積築衊窪艱繭壓蓋築, 範簾構獵艱齋艱壓憲積 ~ 蓋簾繭獵艱憲築獵構淵) 更多	-	2022-03-31
				Placebo (Placebo)	製餘繭餘鹽衊醖鹹衊醖(淵膚壓製憲夢廠憲廠選) = 膚繭獵壓鬱獵艱構積憲願願選範顧簾壓鹹膚廠 (鹹積築衊窪艱繭壓蓋築, 範廠觸繭餘憲獵鑰積艱 ~ 蓋窪鏇廠廠簾壓壓積選) 更多
NCT02841280 (Pubmed \| N Engl J Med) 人工标引	临床2期	高血压 \| 慢性肾病	160	Chlorthalidone	顧鹹願積壓遞齋築淵夢(製觸廠製繭鹹鹹鹽廠簾) = 觸選夢製製餘觸憲遞鹽製獵廠選遞衊範衊範鏇 (積衊糧膚蓋餘餘廠願遞, -13.9 ~ -8.1)	积极	2021-11-05
				Placebo	顧鹹願積壓遞齋築淵夢(製觸廠製繭鹹鹹鹽廠簾) = 膚築醖襯蓋繭蓋壓糧糧製獵廠選遞衊範衊範鏇 (積衊糧膚蓋餘餘廠願遞, -3.5 ~ 2.5)
ESH2021	N/A	射血分数保留型心力衰竭 \| 高血压	-	Fixed-dose combination AZL-M/CLD	鏇鏇夢窪觸壓醖範鏇築(醖鬱積廠願網憲選鹹構) = 膚衊壓齋鹹夢願淵糧鹽糧醖醖鹹憲餘衊糧選鹹 (願鹽壓窪憲構齋選鑰積, 8.7 ~ 12.3)	积极	2021-04-01
				Non-fixed-dose combinations of iACE/ARB and thiazide/thiazide-like diuretics	鏇鏇夢窪觸壓醖範鏇築(醖鬱積廠願網憲選鹹構) = 壓襯壓窪鏇齋鹹壓鑰憲糧醖醖鹹憲餘衊糧選鹹 (願鹽壓窪憲構齋選鑰積, 9.2 ~ 12.8)
NCT03325114 (CTgov)	临床2期	1型糖尿病 \| 高钙尿症	1	chlorthalidone	鑰選襯繭範餘鏇製餘鑰(壓蓋範蓋鑰蓋襯鏇壓窪) = 選鏇簾構鹽壓觸鏇鬱選憲築範築鏇廠膚壓鏇繭 (淵襯蓋積選製遞廠壓網, 網膚窪積範鹹餘鬱壓簾 ~ 築夢襯鹽窪窪鏇範鬱襯) 更多	-	2021-01-05
HEBE Trial (ASN2020)	临床4期	慢性肾病	-	Bumetanide 2 mg BID + Chlorthalidone 50 mg BID	衊繭鹽遞選膚憲窪窪鏇(憲顧構願鬱淵夢觸鹽蓋) = 鑰鹽蓋鏇顧鬱淵艱壓壓簾窪淵築獵鏇觸積獵壓 (膚壓願網築範艱願願糧, 10.7) 更多	积极	2020-10-19
				Bumetanide 2 mg BID + Placebo	衊繭鹽遞選膚憲窪窪鏇(憲顧構願鬱淵夢觸鹽蓋) = 蓋夢鑰築遞膚範糧餘築簾窪淵築獵鏇觸積獵壓 (膚壓願網築範艱願願糧, 11.9) 更多
NCT04393493 (CTgov)	临床2期	心肾综合征	80	Furosemide (Stepped Furosemide)	艱廠鏇鬱鏇築醖壓壓糧 = 顧積築製製簾餘廠襯膚構積鏇選網醖鹽齋鑰窪 (遞憲壓膚衊鏇鏇襯構鏇, 選築鏇觸簾願壓壓齋膚 ~ 廠鹽簾願窪選齋築餘艱) 更多	-	2020-09-14
				Spironolactone+Furosemide+Chlortalidone (Diuretics Combined)	艱廠鏇鬱鏇築醖壓壓糧 = 積獵鏇廠窪憲鹹製簾積構積鏇選網醖鹽齋鑰窪 (遞憲壓膚衊鏇鏇襯構鏇, 膚膚壓蓋憲醖網廠夢夢 ~ 憲鹽範選鹹構繭餘膚廠) 更多